IONIS PHARMACEUTICALS INC (IONS:NASDAQ)
$54.65 -0.08 (-0.1462%)
Analysed IONIS PHARMACEUTICALS INC (IONS:NASDAQ) News Sources
Panic grips Ionis Pharmaceuticals investors amid bad news spree
12-07-2026
thestreet.com
Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer’s?
13-07-2026
yahoo.com
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
13-07-2026
yahoo.com
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
13-07-2026
marketbeat.com
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details
13-07-2026
yahoo.com
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
14-07-2026
yahoo.com
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
14-07-2026
yahoo.com
Morgan Stanley Raises its Price Target on Alnylam (ALNY)
14-07-2026
yahoo.com
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'
14-07-2026
yahoo.com
Ionis to hold second quarter 2026 financial results webcast
15-07-2026
yahoo.com
What is the current price of IONIS PHARMACEUTICALS INC (IONS:NASDAQ)?
The current price of IONIS PHARMACEUTICALS INC (IONS:NASDAQ) is $54.65.
IONIS PHARMACEUTICALS INC (IONS:NASDAQ) absolute price change since previous trading day?
The absolute price change of IONIS PHARMACEUTICALS INC (IONS:NASDAQ) since the previous trading day is $-0.08.
IONIS PHARMACEUTICALS INC (IONS:NASDAQ) percentage price change since previous trading day?
The percentage price change of IONIS PHARMACEUTICALS INC (IONS:NASDAQ) since the previous trading day is -0.1462%.
What is the most recent average sentiment score for IONIS PHARMACEUTICALS INC (IONS:NASDAQ)?
The most recent average sentiment score for IONIS PHARMACEUTICALS INC (IONS:NASDAQ) is 68 out of 100.
What is the most recent average sentiment for IONIS PHARMACEUTICALS INC (IONS:NASDAQ)?
The most recent sentiment for IONIS PHARMACEUTICALS INC (IONS:NASDAQ) is .
SEC-8K** Filing Available For IONIS PHARMACEUTICALS INC (IONS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.